| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0021-9150(03)00088-1 |
| P698 | PubMed publication ID | 12732395 |
| P2093 | author name string | Wolfgang Koenig | |
| Branka Zegura | |||
| Irena Keber | |||
| Miran Sebestjen | |||
| P2860 | cites work | Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 |
| Coagulation activation following estrogen administration to postmenopausal women | Q28212909 | ||
| Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group | Q29615228 | ||
| C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women | Q29616306 | ||
| Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness | Q33658740 | ||
| Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection | Q33683302 | ||
| Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women | Q34067367 | ||
| Early menopause and the risk of myocardial infarction. | Q34287899 | ||
| Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence | Q34748119 | ||
| Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group | Q39522420 | ||
| Hormone replacement therapy and increased plasma concentration of C-reactive protein | Q40801238 | ||
| C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study | Q40828366 | ||
| On some Late Effects of Bilateral Oophorectomy in the Age Range 15–30 Years | Q41911198 | ||
| Menopause and coronary heart disease. The Framingham Study | Q42072645 | ||
| The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study | Q42620817 | ||
| Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women | Q43758821 | ||
| Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study | Q43788768 | ||
| MicroCRP: a highly sensitive CRP method applied in the monitoring of renal allograft recipients | Q49070122 | ||
| The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. | Q51572796 | ||
| Prospective evaluation of the systemic immune response following abdominal, vaginal, and laparoscopically assisted vaginal hysterectomy. | Q53941068 | ||
| Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: Comparison with conventional oral estrogens used for hormone replacement | Q55879652 | ||
| Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease | Q57751651 | ||
| Elevated C-reactive protein levels in overweight and obese adults | Q57830181 | ||
| The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina | Q58230388 | ||
| EFFECTS OF ESTROGEN REPLACEMENT THERAPY ON THROMBIN GENERATION | Q62607064 | ||
| Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins | Q68077029 | ||
| Biologic effects of transdermal estradiol | Q70140885 | ||
| Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease | Q71505808 | ||
| Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women | Q73090822 | ||
| Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis | Q73783163 | ||
| Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis | Q73833388 | ||
| Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial | Q73965928 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 123-129 | |
| P577 | publication date | 2003-05-01 | |
| P1433 | published in | Atherosclerosis | Q4813570 |
| P1476 | title | Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis | |
| P478 | volume | 168 |
| Q37338824 | Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen |
| Q42487474 | Association of endogenous hormones with C-reactive protein, fibrinogen, and white blood count in post-menopausal women |
| Q46678880 | Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study |
| Q28200344 | C-reactive protein (CRP)-lowering agents |
| Q35549901 | Diet and C-reactive protein |
| Q36359547 | Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article |
| Q40516881 | Effects of oestrogen replacement therapy on serum C-reactive protein levels in hysterectomised women |
| Q46813482 | Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer |
| Q35207988 | High Sensitivity C - Reactive Protein is Associated with Diastolic Dysfunction in Young African Americans without Clinically Evident Cardiac Disease |
| Q35918730 | Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease |
| Q37781263 | Hormone replacement therapy and the adolescent |
| Q35680612 | Hormone therapy and Alzheimer's disease: benefit or harm? |
| Q81002469 | Is the WHI relevant to HRT started in the perimenopause? |
| Q43028519 | Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy |
| Q28268346 | Pharmacology of estrogens and progestogens: influence of different routes of administration |
| Q37997819 | Respiratory health in women: from menarche to menopause |
| Q37072758 | Role of aging versus the loss of estrogens in the reduction in vascular function in female rats |
| Q34196350 | Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women |
| Q46914080 | The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial |
| Q35602242 | The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial |
| Q38370885 | The effects of pituitary and thyroid disorders on haemostasis: potential clinical implications |
| Q52565586 | Transdermal estradiol for the management of refractory uremic bleeding. |
| Q55267187 | miR-494 Contributes to Estrogen Protection of Cardiomyocytes Against Oxidative Stress via Targeting (NF-κB) Repressing Factor. |
Search more.